| Dr Christopher Dwight Huston, MD | |
|
111 Colchester Ave, Burlington, VT 05401-1473 | |
| (802) 847-2264 | |
| Not Available |
| Full Name | Dr Christopher Dwight Huston |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 30 Years |
| Location | 111 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033122882 | NPI | - | NPPES |
| 0VN1614 | Medicaid | VT | |
| 01766150 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 042-000-95-13 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.
Proposals for the UK-wide introduction of the new European health insurance card are being published today.
Bristol-Myers Squibb and ZymoGenetics, Inc. have announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.
Human cytomegalovirus is a leading cause of birth defects and transplant failures. As it's evolved over time, this virus from the herpes family has found a way to bypass the body's defense mechanisms that usually guards against viral infections. Until now, scientists couldn't understand how it manages to do so.
Tissue Genesis, Inc., an emerging leader in adult stem cell and regenerative medicine, announced today that it has begun clinical trials for peripheral vascular disease (PVD) with adipose (fat) derived adult stem cell-coated vascular grafts at the University of Louisville Hospital. Tissue Genesis is the first to initiate a FDA-approved trial using the patient's own adipose-derived adult stem cells (ASCs) prepared at the point-of-care.
› Verified 9 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.
Proposals for the UK-wide introduction of the new European health insurance card are being published today.
Bristol-Myers Squibb and ZymoGenetics, Inc. have announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.
Human cytomegalovirus is a leading cause of birth defects and transplant failures. As it's evolved over time, this virus from the herpes family has found a way to bypass the body's defense mechanisms that usually guards against viral infections. Until now, scientists couldn't understand how it manages to do so.
Tissue Genesis, Inc., an emerging leader in adult stem cell and regenerative medicine, announced today that it has begun clinical trials for peripheral vascular disease (PVD) with adipose (fat) derived adult stem cell-coated vascular grafts at the University of Louisville Hospital. Tissue Genesis is the first to initiate a FDA-approved trial using the patient's own adipose-derived adult stem cells (ASCs) prepared at the point-of-care.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Dwight Huston, MD 60 Temple St, Burlington, VT 05401-1138 Ph: () - | Dr Christopher Dwight Huston, MD 111 Colchester Ave, Burlington, VT 05401-1473 Ph: (802) 847-2264 |
News Archive
Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.
Proposals for the UK-wide introduction of the new European health insurance card are being published today.
Bristol-Myers Squibb and ZymoGenetics, Inc. have announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.
Human cytomegalovirus is a leading cause of birth defects and transplant failures. As it's evolved over time, this virus from the herpes family has found a way to bypass the body's defense mechanisms that usually guards against viral infections. Until now, scientists couldn't understand how it manages to do so.
Tissue Genesis, Inc., an emerging leader in adult stem cell and regenerative medicine, announced today that it has begun clinical trials for peripheral vascular disease (PVD) with adipose (fat) derived adult stem cell-coated vascular grafts at the University of Louisville Hospital. Tissue Genesis is the first to initiate a FDA-approved trial using the patient's own adipose-derived adult stem cells (ASCs) prepared at the point-of-care.
› Verified 9 days ago
Nadia Ghallab, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Beach Conger, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 617 Riverside Ave, Burlington, VT 05401 Phone: 802-864-6309 Fax: 802-860-4313 | |
Beth Diane Kirkpatrick, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fletcher Allen Health Care, Burlington, VT 05401 Phone: 802-847-4594 | |
Dr. Richard Frank Branda, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1 S. Prospect St, Burlington, VT 05401 Phone: 802-847-3827 Fax: 802-847-3510 | |
Lauren Suggs, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Magdalena Anna Zeglin, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 |